End-of-day quote
Other stock markets
|
||
- | - |
2023 | Alteogen Inc. Announces Clinical Trial of Tergase Showed Zero Incidence of ADA | CI |
2023 | ALTEOGEN Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
Sales 2024 * | 75.5B 55.34M 0 | Sales 2025 * | 156B 114M 0 | Capitalization | 9,580B 7.02B 0 |
---|---|---|---|---|---|
Net income 2024 * | 13B 9.53M - | Net income 2025 * | 62B 45.45M - | EV / Sales 2024 * | 127 x |
Net cash position 2024 * | 10B 7.33M 0 | Net cash position 2025 * | 63B 46.18M 0 | EV / Sales 2025 * | 61 x |
P/E ratio 2024 * |
704
x | P/E ratio 2025 * |
150
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 68.48% |
Managers | Title | Age | Since |
---|---|---|---|
Sun-Jae Park
CEO | Chief Executive Officer | 69 | 08-05-12 |
Sang-Woo Kang
DFI | Director of Finance/CFO | 58 | 20-05-31 |
Gyu-Wan Kim
CTO | Chief Tech/Sci/R&D Officer | 58 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Sun-Jae Park
CEO | Chief Executive Officer | 69 | 08-05-12 |
Jong-In Choi
BRD | Director/Board Member | 59 | 21-03-28 |
In-Young Go
BRD | Director/Board Member | 68 | 21-03-28 |
1st Jan change | Capi. | |
---|---|---|
-3.20% | 86.16B | |
+2.76% | 40.17B | |
-17.49% | 31.47B | |
+54.44% | 25.24B | |
-13.13% | 15.82B | |
-9.12% | 11.96B | |
-15.45% | 11.89B | |
-42.56% | 11.61B | |
+4.87% | 8.84B |